Back to search results

Tissue Repository for Cutaneous T-cell Lymphoma (CTCL) Research

This study is creating a collection of tissue samples from people with Cutaneous T-cell Lymphoma (CTCL), Lymphomatoid Papulosis (LYP), and Sézary Syndrome (SS). These samples will help scientists better understand how T cells change in these conditions. Researchers will also collect samples from people without these conditions to compare. This collection will be used for future studies to develop new and more effective treatments. You may be able to join if you are 18 or older and have a new, progressive, or relapsed diagnosis of CTCL or LYP, or if you have Sézary Syndrome or stage IV B CTCL with blood involvement. The main goal is to see how many biological samples are collected over two years.

Study design
This is an observational study, meaning researchers will collect information without giving any specific treatments. The study plans to enroll 400 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures the number of biological specimen collections at 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02840747

Tissue Repository: CTCL Collection Protocol

Recruiting
Not specifiedAges 18+Observational
Columbia University
~400 participants
Updated 2025-11-04 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of biological specimen collections
Measured over 2 years

Conditions

Lymphoma, T-Cell, Cutaneous
Lymphomatoid Papulosis
Sézary Syndrome

Explore related trials

Lymphomatoid PapulosisPrimary Cutaneous T-Cell Non-Hodgkin LymphomaSezary SyndromeCD4/CD8 ratioCD4 Gene

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Larisa J. Geskin, MD · PRINCIPAL_INVESTIGATOR · Columbia University

Who to contact

Larisa J. Geskin, MD
[email protected]
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with CTCL or Lymphomatoid Papulosis (LYP): a clinical or histologic diagnosis of a) newly diagnosed, b) progressive, or c) relapsed CTCL or LYP who are initiating or changing therapy.
Patients with Sézary Syndrome (SS) or stage IV B CTCL as defined by blood involvement on flow cytometry or morphology: (1) ≥1000/μL Sézary cells by morphology; (2) Cluster of differentiation 4 (CD4)/cluster of differentiation 8 (CD8) ratio ≥10; (3) CD4+cluster of differentiation 7 (CD7)- cells ≥40 percent; (4) or CD4+cluster of differentiation 26 (CD26)- cells ≥30 percent.
Ability to understand and willing to sign a willing informed consent document.
Age ≥ 18 years.
Matched for sex, and age +/- 10 years.
Ability to sign informed consent document.
Patients with or without benign inflammatory skin conditions including, but not limited to, eczema, psoriasis, or dermatitis or Patients without skin conditions requiring treatment with systemic immunosuppressive, biologic, or chemotherapeutic agents.

Exclusion

Patients with a history of previous lymphoma other than CTCL or SS or LYP.
Medical illnesses with potential suppressive or activating impact on immune and bowel function as judged by the investigator.
Current, viable pregnancy.
Anemia with a documented hemoglobin laboratory value of \<7.5 g/dl within the past 6 months.
Previous history of CTCL, SS, LYP, or any lymphoma.
Previous history of Human Immunodeficiency Virus (HIV) infection.
Anemia with a documented hemoglobin laboratory value of \<7.5 g/dl within the past 6 months.

What this trial measures

  • Number of biological specimen collections2 years

    This is a collection protocol to establish a tissue repository for samples from patients with CTCL.